The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.
The investment will enable the company to enter European markets as well as enhance margins in current markets
The 9th World Ayurveda Congress and Arogya Expo 2022 aims to showcase the efficacy and strength of the AYUSH systems of medicine at the global level
The funds raised through the issue will be utilised to meet the working capital requirements to fund the company's expansion plans, entering new geographies and for general corporate purposes
Expanded capacity in Nansha, China will support mid-scale manufacturing to ensure a smooth transition between early-phase and large-scale commercial production
The laboratory has the capacity to conduct 30,000+ tests in a month ranging from simple routine tests to semi-specialized and specialized tests
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
The inspection of the facility resulted in issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Subscribe To Our Newsletter & Stay Updated
